Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
MDHAR, DHAR, APX and GR activity of VA13 were augmented by 125% 125%, 122% and 124% under MDS and 379%, 375%, 371% and 375% under SDS conditions, whereas MDHAR, DHAR, APX and GR activity of VA15 were augmented by 45% 40%, 37% and 2% under MDS and 70%, 63%, 64% & 20% under SDS conditions, respectively compared to control condition
The website is easy to use, and delivery is fast
Studies suggest ascorbic acid derivatives may suppress inflammatory cytokine pathways including interleukin-33, potentially benefiting barrier-compromised skin states